MedTrace Logo

PET/MR Evaluation of Regression Grading After Neoadjuvant Therapy for Rectal Cancer

NCT06318234 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2024-03-19

No results posted yet for this study

Summary

This project aims to evaluate the role of 18F-FAPI combined with 18F-FDG PET/MRI imaging in quantitatively and accurately evaluating the grading of rectal cancer after SCRT neoadjuvant therapy in patients with advanced rectal cancer as the research object, with postoperative histopathological analysis as the reference index, and to assess the ability of patients to achieve pCR. A diagnostic model and evaluation system will also be constructed.

Conditions

Interventions

DIAGNOSTIC_TEST

18F-FAPI，18F-FDG

FAPI and FDG combined with PET/MR imaging in patients with rectal cancer after neoadjuvant therapy

Sponsors & Collaborators

  • Xiao Chen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06318234 on ClinicalTrials.gov